GleamWall
中文EN

AVTX Avalo Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1534120 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-77.1%
TTM net income YoY-11.4%
TTM EPS YoY81.6%
Revenue 3-yr CAGR-56.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-15,536.1%
Net margin-7,965.8%
FCF margin-11,123.8%
EBITDA margin-15,497.7%

Returns

ROE-50.1%
ROA-40.9%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets11.7%
Debt / equity0.00x
Current ratio19.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.40x
Accruals ratio16.2%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$59,000$0——$192,000
Cost of revenue—————$0——
R&D expense$15.05M$23.42M$14.05M$13.27M$13.62M$14.07M$9.12M$8.18M
SG&A expense$8.35M$8.10M$6.85M$6.53M$5.58M$5.24M$5.55M$5.23M
Operating income-$23.40M-$31.52M-$20.90M-$19.74M-$19.20M-$19.32M-$14.67M-$13.31M
Pretax income-$18.94M-$36.34M-$19.62M-$13.59M-$30.61M-$20.75M-$13.14M-$35.23M
Income tax$7,000$18,000$12,000$130,000$11,000$16,000$8,000$114,000
Net income-$18.95M-$36.36M-$19.63M-$13.72M-$30.62M-$20.77M-$13.15M-$35.34M
EBITDA-$23.38M-$31.50M-$20.88M-$19.73M-$19.14M-$19.18M-$14.53M-$13.24M
EPS (basic)-0.34-0.83-0.98—-2.19-1.92-1.25—
EPS (diluted)-0.34-0.83-0.98—-2.19-1.92-1.25—
Weighted avg. shares (diluted)55.06M43.60M20.11M—14.00M10.83M10.51M—
Balance sheet
Cash & equivalents$64.99M$85.38M$24.99M$15.86M$26.96M$42.29M$125.05M$134.70M
Short-term investments$327.98M$314.89M$57.01M$82.48M$84.65M$70.97M—$0
Current assets$400.74M$407.93M$88.83M$105.29M$113.85M$115.19M$126.94M$138.89M
Goodwill$10.50M$10.50M$10.50M$10.50M$10.50M$10.50M$10.50M$10.50M
Total assets$481.43M$490.78M$99.89M$116.46M$125.10M$126.58M$138.52M$150.73M
Current liabilities$24.09M$21.13M$11.60M$12.94M$7.97M$9.26M$5.62M$6.96M
Total liabilities$44.88M$42.12M$31.57M$33.41M$33.55M$22.01M$15.91M$17.70M
Shareholders' equity$436.55M$448.66M$68.32M$83.05M$91.55M$104.57M$122.61M$133.03M
Shares outstanding53.92M52.90M24.64M18.51M17.83M10.84M10.83M10.47M
Cash flow statement
Operating cash flow-$11.54M-$19.99M-$17.69M-$14.25M-$16.36M-$11.39M-$9.46M-$15.04M
Capital expenditure———————$0
Free cash flow———————-$15.04M
Investing cash flow-$11.23M-$329.93M$25.50M$2.40M-$13.26M-$70.86M$0$0
Financing cash flow$2.54M$410.21M$1.40M$687,000$14.37M-$469,000$0$67.71M
Depreciation & amortization$18,000$17,000$17,000$16,000$59,000$134,000$135,000$68,000
Stock-based compensation$5.22M$5.31M$3.58M$4.51M$3.15M$2.72M$3.24M$2.90M

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.